NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that a Phase II clinical trial of IMC-A12, ImClone’s fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in patients with advanced hepatocellular cancer (liver cancer) has opened for patient enrollment. This study is being carried out at the Memorial Sloan Kettering Cancer Center located in New York, NY.
